

ASX ANNOUNCEMENT

8 January 2016

MedAdvisor signs partnership agreement with Epilepsy Queensland Inc.

Melbourne, 8 January 2016: MedAdvisor Limited (**ASX:MDR**) an Australian software developer focused on improving health outcomes by placing patients at the centre of connected health platforms, today announces it has signed a Memorandum of Understanding (MOU) with Epilepsy Queensland Inc.

This agreement will see MedAdvisor and Epilepsy Queensland Inc collaborating to help improve personal medication management of epilepsy patients and their carers, by promoting the use of MedAdvisor's free medication management app. It will also create a number of tailored solutions to assist Epilepsy Queensland Inc.

According to the World Health Organisation, epilepsy is the world's most common serious brain disorder. Epilepsy affects nearly 3.5% of Australians and nearly 800,000 people in Australia will be diagnosed with epilepsy at some stage in life. Currently it is estimated that over 250,000 Australians are living with epilepsy.

Epilepsy Queensland Inc.'s key goals are to increase awareness of epilepsy in the community and support people with epilepsy. The organisation provides counselling, information, education, training and advocacy services to people with epilepsy and their families, schools, health professionals and disability services.

MedAdvisor has created a software platform that helps individuals to monitor their medication use, connecting to their pharmacy of choice, automatically retrieving medication records and activating an intelligent training, information and reminder system to ensure correct and reliable medication use.

Poor medication adherence has been identified as one of the most significant and costly problems faced by governments and major healthcare providers in developed nations. In the case of epilepsy, appropriate use of medication is a key component of current gold standard therapy to help sufferers live seizure-free.

MedAdvisor CEO, Mr Robert Read, said: "In Australia, medication adherence in epilepsy is typically quite low, with just 60% of medication doses taken as prescribed. We are very pleased to be working with Epilepsy Queensland to assist epilepsy patients and their carers manage their medication safely and effectively.

"Epilepsy patients using the MedAdvisor app are 15-20 per cent more adherent, meaning they are taking more of their prescribed doses of medication. Better adherence results in better health outcomes for patients."

Ms Helen Whitehead, CEO of Epilepsy Queensland, said: "We are excited about working closely with MedAdvisor during 2016. We believe the MedAdvisor app is an important innovation that will help patients and their carers to make a measurable difference to health outcomes for people

with epilepsy. The app will facilitate some tailored information which will help bring epilepsy out of the shadows, and we look forward to promoting it to our community.”

A quarter of all Australian pharmacies are actively promoting the MedAdvisor platform to their customers, and more than 100,000 users are managing their medication via MedAdvisor’s free app Australia-wide.

-ENDS-

About MedAdvisor

MedAdvisor is an Australian software systems developer focused on addressing gaps in personal medication adherence. MedAdvisor’s free app connects to pharmacy dispensing systems to automatically retrieve medication records and drive an intelligent training, information and reminder system to ensure correct and reliable medication use. It was the most downloaded pharmacy or medication-related app in Apple and Android stores in Australia in 2014 and 2015, and is being used by more than 100,000 Australians. A quarter of all Australian pharmacies subscribe to the MedAdvisor software platform.

MedAdvisor has established sales and marketing partnerships with private health insurer, BUPA, and has training and service contracts with top tier global pharmaceutical companies, including GSK, AstraZeneca, UCB, Apotex and Amgen.

For more information

Robert Read
MedAdvisor
Tel: +61 3 9095 3036
robertr@medadvisor.com.au

Peter Bennetto
Exalt Resources Ltd
Tel: +61 8 9481 0389
info@exaltresources.com.au

Catie Corcoran
Buchan Consulting
Tel: +61 2 9237 2807
ccorcoran@buchanwe.com.au

Nicholas Downes
Peloton Capital
Tel: +61 2 8651 7802
nicholas.downes@pelotoncapital.com.au